- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-124/15: Judgment of the Court (First Chamber) of 17 February 2016 (request for a preliminary ruling from the Finanzgericht Hamburg — Germany) — Salutas Pharma GmbH v Hauptzollamt Hanover (Reference for a preliminary ruling — Common Customs Tariff — Tariff classification — Combined Nomenclature — Heading 3004 — Effervescent tablets containing 500 mg of calcium — Level of substance per recommended daily dose significantly higher than the recommended daily allowance to maintain general health or well-being)
ECLI:EU:UNKNOWN:62015CA0124
62015CA0124
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
25.4.2016
Official Journal of the European Union
C 145/12
(Case C-124/15) (<span class="super">1</span>)
((Reference for a preliminary ruling - Common Customs Tariff - Tariff classification - Combined Nomenclature - Heading 3004 - Effervescent tablets containing 500 mg of calcium - Level of substance per recommended daily dose significantly higher than the recommended daily allowance to maintain general health or well-being))
(2016/C 145/13)
Language of the case: German
Referring court
Parties to the main proceedings
Applicant: Salutas Pharma GmbH
Defendant: Hauptzollamt Hanover
Operative part of the judgment
The Combined Nomenclature in Annex I to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and the statistical nomenclature and on the Common Customs Tariff, as amended by Commission Regulation (EC) No 1006/2011 of 27 September 2011 must be interpreted as meaning that a product, such as effervescent tablets with a calcium content of 500 mg per tablet that is used for the prevention and treatment of a calcium deficiency and to support a special therapy for the prevention and treatment of osteoporosis, and for which the maximum recommended daily dose for adults indicated on the label is 1 500 mg, falls within heading 3004 of that nomenclature.
*
Language of the case: German.
* * *